HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Viloxazine in the treatment of endogenous depression. A standard (amitriptyline) controlled clinical study.

Abstract
In a double-blind clinical trial with 20 patients suffering from endogenous depression statistically significant changes (improvement) were present in the scores of all assessment instruments. Although no statistically significant differences occurred between the groups, significant improvement on the HAM-D occurred earlier for amitriptyline and significant improvement occurred earlier on HAM-A for viloxazine. 2 patients were discontinued due to adverse reactions; one for nausea and vomiting while receiving viloxazine and one for paroxysmal atrial tachycardia while receiving amitriptyline. The same number of TES occurred for each group with seven unique to viloxazine (numbness, tingling, palpitation, ejaculation difficulty, nausea/vomiting, diarrhea, epigastric pain and gustatory disturbances) and seven unique to amitriptyline (insomnia, irritability, syncope, tremor, nasal congestion, orthostatic hypertension and paroxysmal atrial tachycardia). Other than for 1 patient who developed syncope and orthostatic hypotension and the patient who developed paroxysmal atrial tachycardia, there were no clinically significant changes in pulse rate, blood pressure and weight. There were no clinical laboratory findings with either drug that were judged to be pathological.
AuthorsW M Petrie, T A Ban, W H Wilson, R C Jamieson, W Guy
JournalInternational pharmacopsychiatry (Int Pharmacopsychiatry) Vol. 17 Issue 4 Pg. 280-6 ( 1982) ISSN: 0020-8272 [Print] Switzerland
PMID7185772 (Publication Type: Journal Article)
Chemical References
  • Morpholines
  • Amitriptyline
  • Viloxazine
Topics
  • Adolescent
  • Adult
  • Amitriptyline (adverse effects, therapeutic use)
  • Bipolar Disorder (drug therapy)
  • Depressive Disorder (drug therapy, psychology)
  • Depressive Disorder, Major (drug therapy)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Morpholines (therapeutic use)
  • Psychiatric Status Rating Scales
  • Viloxazine (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: